Zebinix non-inferior to current standard of care in epilepsy
Eisai and Bial’s epilepsy drug Zebinix has shown effectiveness on par with that of the current standard of care in newly diagnosed focal epilepsy patients.
Read More
Tag: Zebinix
Real world data back use of Eisai, Bial’s Zebinix in epilepsy
A pooled analysis of real-world data from over 2,000 patients with epilepsy has shown that Eisai and Bial’s Zebinix is safe and effective when switching from previous treatment with carbamazepine or oxcarbazepine.
Read More
EU regulators widen approval for Zebinix
The European Medicines Agency has cleared use of Bial and Eisai’s sodium channel blocker Zebinix for use as a once-daily monotherapy to treat adults with newly-diagnosed partial-onset epilepsy, widening its treatment scope in the region.
Read More
- Storm Therapeutics and AlidaBio launch collaboration to advance RNA‑targeting cancer therapies
- Excellence adventure
- MHRA approves Nucala for eosinophilic COPD in adults on triple therapy
- Bial launches new sublingual Parkinson’s treatment in UK
- Acesion Pharma launches phase 2 trial of AP31969 in atrial fibrillation
